Robert C. Green, MD, MPH
Professor of Medicine;
Director, G2P Research Program;
Associate Director for Research, Partners Personalized Medicine
Division of Genetics, Department of Medicine
Brigham and Women’s Hospital, Broad Institute and Harvard Medical School
Robert C. Green, MD, MPH
Professor of Medicine; Director, G2P Research Program; Associate Director for Research, Partners Personalized Medicine, Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Broad Institute and Harvard Medical School
Robert C. Green, MD, MPH is a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School.
Dr. Green is principal investigator of the NIH-funded REVEAL Study, in which a cross-disciplinary team has conducted 4 separate multi-center randomized clinical trials since 2000, collectively enrolling 1100 individuals in order to explore emerging themes in translational genomics. Dr. Green also co-directs the NIH-funded PGen Study, one of the first prospective studies of direct-to-consumer genetic testing services. He is principal investigator of the MedSeq Project, the first NIH-funded randomized trial to explore the use of whole genome sequencing in the clinical practice of medicine and co-directs the BabySeq Project, the first NIH-funded trial of sequencing in newborns. The MedSeq and BabySeq Projects apply genome sequencing both in patients who are affected with hereditary disease and in those who are healthy, in order to study downstream impact on health, behavior and health care costs.
Dr. Green is currently Associate Director for Research of the Partners Center for Personalized Genetic Medicine, a Board Member of the Council for Responsible Genetics and a member of the Informed Cohort Oversight Boards for both the Children’s Hospital Boston Gene Partnership Program and the Coriell Personalized Medicine Collaborative. He was the lead author of the recently published recommendations from the American College of Medical Genetics and Genomics for management of incidental findings in clinical sequencing.
Howard J. Jacob, PhD
Vice President, Head of Genomic Research and Head of Data Convergence, AbbVie
Howard J. Jacob, PhD
Vice President, Head of Genomic Research and Head of Data Convergence, AbbVie
Howard Jacob, Ph.D., is Vice President, Head of Genomic Research and Head of Data Convergence at AbbVie, one of the world’s leading biopharmaceutical companies.
Dr. Jacob joined AbbVie in January 2018 to cultivate the company’s growing genomics program. An accomplished leader in the field of genetics and genomics, he has published more than 250 peer-reviewed articles in his academic career, focusing on the genetic mapping of complex diseases and building genomic resources and tools to better understand the functional impact of genetic variation. As Head of Data Convergence, he pushes AbbVie’s data and digital strategy forward by connecting resources and expertise within the company’s R&D function – including genomics, external data and clinical and real world evidence – to drive insights into the discovery, development and commercialization of new therapies for patients.
Throughout his career, Dr. Jacob has been a pioneer in translating research into the healthcare ecosystem, bringing genomic medicine to patients in need of answers. In 2009, Dr. Jacob and his team at the Medical College of Wisconsin were the first to use genomic sequencing to save a patient’s (Nicholas Volker) life. Nicholas’ story was highlighted in a Pulitzer Prize winning series in the Milwaukee Journal Sentinel.
Prior to his role at AbbVie, Dr. Jacob served as the Executive Vice President for Genomic Medicine, Chief Genomics Medicine Officer and Faculty Investigator at the HudsonAlpha Institute for Biotechnology. Dr. Jacob led the whole genome sequencing core for the NIH-funded Undiagnosed Disease Network and led the clinical teams at the world’s first stand-alone genomic medicine clinic, as well as a whole genome clinical sequencing lab. Prior to his role there, Dr. Jacob was the founding director of the Human and Molecular Genetics Center at Medical College of Wisconsin, which grew from two to a team of 30 faculty members. He has also founded four companies and participated on the advisory boards for numerous academic and commercial organizations.
Dr. Jacob’s passion for improving the lives of critically ill patients has been the catalyst for his determination to bring whole genome sequencing into the clinical setting to affect patient care, and in his new role to discover therapeutic solutions for some of the most difficult diseases. He earned his Ph.D. at the University of Iowa and did post-doc research with Eric Lander and Victor Dzau at MIT, Harvard and Stanford.